Global Antibiotics Market - Distribution by Type of Drug Class (Aminoglycosides, Cephalosporins, Fluoroquinolones, Macrolides, Oxazolidinones, Penicillins, Sulphonamides, Tetracyclines and Other Drug Classes), Target Disease Indication (Bacterial Infections, Skin Infections, Gastrointestinal Infections, Hematological Infections, Nephrological Infections, Pulmonary Infections, Reproductive Tract Infections, Respiratory Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infections and Other Bacterial Infections), Type of Therapy (Monotherapies and Combination Therapies), Route of Administration (Intravenous and Oral), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World), and Drug-wise Sales: Industry Trends and Global Forecasts, 2023-2035
The global antibiotics market is expected to reach USD 36 billion in 2023 anticipated to grow at a CAGR of 1.2% during the forecast period 2023-2035.
Bacterial infections stand as a primary contributor to global mortality, accounting for one out of every eight deaths worldwide. This prevalence predominantly stems from the escalation of resistant pathogenic bacteria against conventional treatments. The Centers for Disease Control and Prevention (CDC) notes that managing infections from six multi-drug resistant bacteria incurs an annual cost of over USD 4.6 billion in the United States alone. Antibiotics, sourced from biological or chemical origins, play a critical role in preventing and treating various bacterial infections. Recent advancements have led to the approval of diverse broad-spectrum and narrow-spectrum antibiotics designed to combat a range of bacterial diseases such as anthrax, botulism, cholera, gonorrhea, meningitis, pneumonia, tetanus, tuberculosis, and syphilis. Nevertheless, the development of antibiotic drugs encounters numerous challenges, including the emergence of multi-drug resistant bacteria, shortages—especially of penicillin and amoxicillin—and concerns regarding safety and efficacy. To address these challenges, stakeholders within the industry have actively engaged in research and development endeavors. Additionally, regulatory bodies such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and the United States Food and Drug Administration (USFDA) have initiated campaigns to promote appropriate antibiotic usage and extend support to the industry. Through the collaborative efforts of industry and non-industry entities, accompanied by escalating concerns surrounding antimicrobial resistance, the global antibiotics market is anticipated to experience significant growth in the projected period.
Report Coverage
Bacterial infections stand as a primary contributor to global mortality, accounting for one out of every eight deaths worldwide. This prevalence predominantly stems from the escalation of resistant pathogenic bacteria against conventional treatments. The Centers for Disease Control and Prevention (CDC) notes that managing infections from six multi-drug resistant bacteria incurs an annual cost of over USD 4.6 billion in the United States alone. Antibiotics, sourced from biological or chemical origins, play a critical role in preventing and treating various bacterial infections. Recent advancements have led to the approval of diverse broad-spectrum and narrow-spectrum antibiotics designed to combat a range of bacterial diseases such as anthrax, botulism, cholera, gonorrhea, meningitis, pneumonia, tetanus, tuberculosis, and syphilis. Nevertheless, the development of antibiotic drugs encounters numerous challenges, including the emergence of multi-drug resistant bacteria, shortages—especially of penicillin and amoxicillin—and concerns regarding safety and efficacy. To address these challenges, stakeholders within the industry have actively engaged in research and development endeavors. Additionally, regulatory bodies such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and the United States Food and Drug Administration (USFDA) have initiated campaigns to promote appropriate antibiotic usage and extend support to the industry. Through the collaborative efforts of industry and non-industry entities, accompanied by escalating concerns surrounding antimicrobial resistance, the global antibiotics market is anticipated to experience significant growth in the projected period.
Report Coverage
- The report examines the antibiotics market by categorizing it according to the type of drug class, target disease indication, type of therapy, route of administration and key geographical regions.
- It conducts an analysis of factors—such as drivers, restraints, opportunities, and challenges—that impact the market's growth trajectory.
- The report evaluates the potential advantages and obstacles within the market, providing insights into the competitive landscape for leading market players.
- Revenue forecasts for market segments are projected across four major regions.
- The executive summary segment provides an overview of the current global antibiotics market and its anticipated development in the medium to long term.
- It offers an introduction to antibiotics, detailing their characteristics, advantages, and classification based on chemical structure, mode of action, activity range, and source. This section encompasses historical perspectives, innovations, mechanisms of action, challenges, and future prospects.
- A comprehensive analysis covers approval years, regions, antibiotic types, mechanisms of action, spectrum of activity, target bacteria, disease indications, source nature, therapy types, administration routes, dosage forms, patient populations, and developer details.
- Similar to the generics analysis, a detailed examination focuses on branded antibiotics. Parameters considered include approval details, antibiotic types, mechanisms, spectrum, target bacteria, disease indications, therapy types, administration routes, dosage forms, patient populations, innovation types, and developer insights.
- An in-depth evaluation of clinical-stage antibiotics includes development statuses, antibiotic types, mechanisms, spectra, target bacteria, disease indications, therapeutic areas, therapy types, administration routes, dosage forms, patient populations, special designations, and developer analyses.
- Detailed profiles of significant players in antibiotic development encompass company overviews, key executives, financial data (if available), product portfolios, recent developments, future outlooks, strategic focus areas, and expert opinions.
- Examination of partnerships between industry stakeholders since 2017, considering partnership types, partners, company sizes, active players, and regional distributions in the antibiotics market.
- Exploration of completed and ongoing antibiotic-related clinical trials based on registration years, trial statuses, phases, patient populations, focus areas, sponsors, geographies, and active industry and non-industry players.
- Insightful analysis of key opinion leaders involved in antibiotic-related clinical trials, focusing on their qualifications, affiliations, geographic locations, target disease indications, prominence based on proprietary and third-party criteria.
- Elaboration on significant trends within the antibiotics industry, including drug pricing, outsourcing patterns, and the impact of COVID-19.
- An analysis of recently approved antibiotics based on parameters such as dosing, efficacy, competition, innovation, price, prevalence, administration route, activity spectrum, therapy type, and target bacteria.
- Bristol Myers Squibb
- Daiichi Sankyo
- GlaxoSmithKline
- Melinta Therapeutics
- Merck
- Pfizer
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1. Overview of Antibiotics
2.2. Characteristics of an Ideal Antibiotic
2.3. Advantages of Antibiotics
2.4. Classification of Antibiotics
2.5. History of Antibiotics
2.6. Innovations in Antibiotics
2.7. Mechanism of Action of Antibiotics
2.8. Challenges associated with the use of Antibiotics
2.9. Future Perspectives
3. MARKET LANDSCAPE: APPROVED ANTIBIOTIC GENERICS
3.1. Approved Antibiotic Generics: Overall Market Landscape
3.1.1. Analysis by Year of Approval
3.1.2. Analysis by Region(s) of Approval
3.1.4. Analysis by Type of Antibiotic (based on Chemical Structure)
3.1.3. Analysis by Type of Antibiotic (based on Drug Class)
3.1.5. Analysis by Mechanism of Action
3.1.6. Analysis by Spectrum of Activity
3.1.7. Analysis by Type of Target Bacteria(s)
3.1.8. Analysis by Target Bacterial Strain(s)
3.1.9. Analysis by Target Disease Indication(s)
3.1.10. Analysis by Nature of Source
3.1.11. Analysis by Type of Therapy
3.1.12. Analysis by Route(s) of Administration
3.1.13. Analysis by Dosage Form(s)
3.1.14. Analysis by Type of Patient Population (based on Age)
3.1.15. Analysis by Type of Patient Population (based on Gender)
3.2. Approved Antibiotic Generics: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Analysis by Location of Headquarters
3.2.4. Most Active Players: Analysis by Number of Approved Generics
4. MARKET LANDSCAPE: APPROVED ANTIBIOTIC BRANDS
4.1. Approved Antibiotic Brands: Overall Market Landscape
4.1.1. Analysis by Year of Approval
4.1.2. Analysis by Region(s) of Approval
4.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
4.1.4. Analysis by Type of Antibiotic (based on Drug Class)
4.1.5. Analysis by Mechanism of Action
4.1.6. Analysis by Spectrum of Activity
4.1.7. Analysis by Type of Target Bacteria
4.1.8. Analysis by Target Bacterial Strain(s)
4.1.9. Analysis by Target Disease Indication(s)
4.1.10. Analysis by Nature of Source
4.1.11. Analysis by Type of Therapy
4.1.12. Analysis by Route(s) of Administration
4.1.13. Analysis by Dosage Form(s)
4.1.14. Analysis by Type of Patient Population (based on Age)
4.1.15. Analysis by Type of Patient Population (based on Gender)
4.1.16. Analysis by Type of Innovation
4.2. Approved Antibiotic Brands: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.4. Analysis by Location of Headquarters
4.2.5. Most Active Players: Analysis by Number of Approved Brands
5. MARKET LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS
5.1. Clinical -Stage Antibiotics: Overall Market Landscape
5.1.1. Analysis by Status of Development
5.1.2. Analysis by Stage of Development
5.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
5.1.4. Analysis by Type of Antibiotic (based on Drug Class)
5.1.5. Analysis by Mechanism of Action
5.1.6. Analysis by Spectrum of Activity
5.1.7. Analysis by Type of Target Bacteria(s)
5.1.8. Analysis by Target Bacterial Strain(s)
5.1.9. Analysis by Target Disease Indication(s)
5.1.10. Analysis by Therapeutic Area(s)
5.1.11. Analysis by Nature of Source
5.1.12. Analysis by Type of Therapy
5.1.13. Analysis by Route(s) of Administration
5.1.14. Analysis by Dosage Form(s)
5.1.15. Analysis by Dosage Strength
5.1.16. Analysis by Dosage Frequency
5.1.17. Analysis by Dosing Period
5.1.18. Analysis by Type of Patient Population (based on Age)
5.1.19. Analysis by Type of Patient Population (based on Gender)
5.1.20. Analysis by Special Designation Received
5.2. Clinical -Stage Antibiotics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Most Active Players: Analysis by Number of Clinical-stage Antibiotics
5.2.5. Most Active Players: Analysis by Number of Preclinical-stage Antibiotics
6. COMPANY PROFILES
6.1. Bristol-Myers Squibb
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Financial Information
6.1.4. Product Portfolio
6.1.5. Recent Developments
6.1.6. Key Strategies
6.1.7. Key Focus Areas
6.1.8. Expert Opinion
6.2. Daiichi Sankyo
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments
6.2.6. Key Strategies
6.2.7. Key Focus Areas
6.2.8. Expert Opinion
6.3. GlaxoSmithKline
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments
6.3.6. Key Strategies
6.3.7. Key Focus Areas
6.3.8. Expert Opinion
6.4. Melinta Therapeutics
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Financial Information
6.4.4. Product Portfolio
6.4.5. Recent Developments
6.4.6. Key Strategies
6.4.7. Key Focus Areas
6.4.8. Expert Opinion
6.5. Merck
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments
6.5.6. Key Strategies
6.5.7. Key Focus Areas
6.5.8. Expert Opinion
6.6. Pfizer
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments
6.6.6. Key Strategies
6.6.7. Key Focus Areas
6.6.8. Expert Opinion
6.7. Concluding Remarks
7. PARTNERSHIPS AND COLLABORATIONS ANALYSIS
7.1. Partnership Models
7.2. Antibiotics: List of Partnerships and Collaborations
7.2.1. Analysis by Year of Partnership
7.2.2. Analysis by Type of Partnership
7.2.3. Analysis by Type of Partner
7.2.4. Analysis by Company Size
7.2.5. Local and International Agreements
7.2.6. Intracontinental and Intercontinental Agreements
7.2.7. Most Active Players: Analysis by Number of Partnerships
7.2.8. Concluding Remarks
8. CLINICAL TRIAL ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Antibiotics: Clinical Trial Analysis
8.2.1. Analysis by Trial Registration Year
8.2.2. Analysis by Trial Status
8.2.3. Analysis by Trial Phase
8.2.4. Analysis by Type of Patient Population (based on Gender)
8.2.5 Word Cloud Analysis: Key Focus Areas
8.2.6. Analysis by Type of Sponsor
8.2.7. Analysis by Geography
8.2.8. Most Active Industry Players: Analysis by Number of Trials
8.2.9. Most Active Non-Industry Players: Analysis by Number of Trials
9. KEY OPINION LEADERS
9.1. Assumptions and Key Parameters
9.2. Methodology
9.3. Antibiotics: Key Opinion Leaders (KOLs)
9.3.1. Analysis by Type of KOL
9.3.2. Analysis by Qualification
9.3.3. Analysis by Type of Organization
9.3.4. Analysis by Affiliated Organization
9.3.5. Analysis by Geographical Location of KOLs
9.3.6. Analysis by Target Disease Indication(s)
9.3.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
9.3.8 Most Prominent KOLs: Peer Group 2 (Other Types of Investigators)
9.3.9. Most Prominent KOLs: Analysis by RA score
9.3.10. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.3.11. Concluding Remarks
10. KEY TRENDS IN ANTIBIOTICS INDUSTRY
10.1. Antibiotics Industry: Drug-Pricing Analysis
10.2. Antibiotics Industry: Outsourcing Trends
10.3. Antibiotics Industry: Impact of COVID-19
11. APPROVED ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.3. Success Protocol Analysis of Recently Approved Antibiotic Brands
11.3.1. Dovprela (TB Alliance)
11.3.1.1. Drug Overview
11.3.1.2. Success Protocol Analysis
11.3.2. Fetroja (Shionogi)
11.3.2.1. Drug Overview
11.3.2.2. Success Protocol Analysis
11.3.4. Kimyrsa (Melinta Therapeutics)
11.3.4.1. Drug Overview
11.3.4.2. Success Protocol Analysis
11.3.5 Recarbrio (Merck)
11.3.5.1. Drug Overview
11.3.5.2. Success Protocol Analysis
11.3.6. Quofenix (Menarini)
11.3.6.1. Drug Overview
11.3.6.2. Success Protocol Analysis
11.3.9 Xenleta (Nabriva Therapeutics)
11.3.9.1. Drug Overview
11.3.9.2. Success Protocol Analysis
11.4. Concluding Remarks
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Antibiotics Market, 2023-2035
12.3.1. Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2035
12.3.1.1. Antibiotics Market for Aminoglycosides, 2023-2035
12.3.1.2. Antibiotics Market for Cephalosporins, 2023-2035
12.3.1.3. Antibiotics Market for Fluoroquinolones, 2023-2035
12.3.1.4. Antibiotics Market for Macrolides, 2023-2035
12.3.1.5. Antibiotics Market for Oxazolidinones, 2023-2035
12.3.1.6. Antibiotics Market for Penicillins, 2023-2035
12.3.1.7. Antibiotics Market for Sulphonamides, 2023-2035
12.3.1.8. Antibiotics Market for Tetracyclines, 2023-2035
12.3.1.9. Antibiotics Market for Other Classes, 2023-2035
12.3.2. Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035
12.3.2.1. Antibiotics Market for Bacterial Infections, 2023-2035
12.3.2.2. Antibiotics Market for Dermatological/ Skin Infections, 2023-2035
12.3.2.3. Antibiotics Market for Gastrointestinal Infections, 2023-2035
12.3.2.4. Antibiotics Market for Hematological Infections, 2023-2035
12.3.2.5. Antibiotics Market for Nephrological Infections, 2023-2035
12.3.2.6. Antibiotics Market for Pulmonary Infections, 2023-2035
12.3.2.7. Antibiotics Market for Reproductive Tract Infections, 2023-2035
12.3.2.8. Antibiotics Market for Respiratory Tract Infections, 2023-2035
12.3.2.9. Antibiotics Market for Sexually Transmitted Diseases, 2023-2035
12.3.2.10. Antibiotics Market for Urinary Tract Infections, 2023-2035
12.3.2.11. Antibiotics Market for Other Bacterial Infections, 2023-2035
12.3.3. Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035
12.3.3.1. Antibiotics Market for Monotherapies, 2023-2035
12.3.3.2. Antibiotics Market for Combination Therapies, 2023-2035
12.3.4. Antibiotics Market: Distribution by Route of Administration, 2023 and 2035
12.3.4.1. Antibiotics Market for Intravenous Therapies, 2023-2035
12.3.4.2. Antibiotics Market for Oral Therapies, 2023-2035
12.3.5. Antibiotics Market: Distribution by Geography, 2023 and 2035
12.3.5.1. Antibiotics Market in North America, 2023-2035
12.3.5.2. Antibiotics Market in Europe, 2023-2035
12.3.5.2. Antibiotics Market in Asia-Pacific, 2023-2035
12.3.5.3. Antibiotics Market in Rest of the World, 2023-2035
12.3.6. Sales Forecast: Approved Antibiotics
12.3.6.1. Aemcolo®: Sales Forecast, 2023-2035
12.3.6.2. Arikayce®: Sales Forecast, 2023-2035
12.3.6.3. Baxdela™: Sales Forecast, 2023-2035
12.3.6.4. Dalacin C: Sales Forecast, 2023-2035
12.3.6.5. Dovprela®: Sales Forecast, 2023-2035
12.3.6.6. Emrok: Sales Forecast, 2023-2035
12.3.6.7. Emrok-O: Sales Forecast, 2023-2035
12.3.6.8. Fetroja®: Sales Forecast, 2023-2035
12.3.6.9. Kimyrsa™: Sales Forecast, 2023-2035
12.3.6.10. Lasvic®: Sales Forecast, 2023-2035
12.3.6.11. Nuzyra®: Sales Forecast, 2023-2035
12.3.6.12. Orbactiv™/Tenkasi: Sales Forecast, 2023-2035
12.3.6.13. Ozanex™: Sales Forecast, 2023-2035
12.3.6.14. Quofenix: Sales Forecast, 2023-2035
12.3.6.15. Recarbrio™: Sales Forecast, 2023-2035
12.3.6.16. Seysara™: Sales Forecast, 2023-2035
12.3.6.17. Solosec®: Sales Forecast, 2023-2035
12.3.6.18. Vabomere™: Sales Forecast, 2023-2035
12.3.6.19. Xenleta™: Sales Forecast, 2023-2035
12.3.6.20. XEPI™: Sales Forecast, 2023-2035
12.3.6.21. Xerava™: Sales Forecast, 2023-2035
12.3.6.22. Xydalba®: Sales Forecast, 2023-2035
12.3.6.23. Youxitai: Sales Forecast, 2023-2035
12.3.6.24. Zemdri™: Sales Forecast, 2023-2035
12.3.6.25. Zerbaxa®: Sales Forecast, 2023-2035
12.3.6.26. Zyvoxam®: Sales Forecast, 2023-2035
12.3.7. Sales Forecast: Clinical-stage Antibiotics
12.3.7.1. Cefepime-Taniborbactam: Sales Forecast, 2023-2035
12.3.7.2. CONTEPO™: Sales Forecast, 2023-2035
12.3.7.3. Gepotidacin (GSK2140944): Sales Forecast, 2023-2035
12.3.7.4. MBK-01: Sales Forecast, 2023-2035
12.3.7.5. MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2035
12.3.7.6. Nafithromycin (WCK 4873): Sales Forecast, 2023-2035
12.3.7.7. RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, 2023-2035
12.3.7.8. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2035
12.3.7.9. Ridinilazole (SMT 19969): Sales Forecast, 2023-2035
12.3.7.10. Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2035
12.3.7.11. Tebipenem HBr: Sales Forecast, 2023-2035
12.3.7.12. WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2035
12.3.7.13. WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2035
12.3.7.14. XNW4107 (Funobactam): Sales Forecast, 2023-2035
12.3.7.15. Zabofloxacin: Sales Forecast, 2023-2035
12.3.7.16. Zoliflodacin (ETX0914): Sales Forecast, 2023-2035
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
2. INTRODUCTION
2.1. Overview of Antibiotics
2.2. Characteristics of an Ideal Antibiotic
2.3. Advantages of Antibiotics
2.4. Classification of Antibiotics
2.5. History of Antibiotics
2.6. Innovations in Antibiotics
2.7. Mechanism of Action of Antibiotics
2.8. Challenges associated with the use of Antibiotics
2.9. Future Perspectives
3. MARKET LANDSCAPE: APPROVED ANTIBIOTIC GENERICS
3.1. Approved Antibiotic Generics: Overall Market Landscape
3.1.1. Analysis by Year of Approval
3.1.2. Analysis by Region(s) of Approval
3.1.4. Analysis by Type of Antibiotic (based on Chemical Structure)
3.1.3. Analysis by Type of Antibiotic (based on Drug Class)
3.1.5. Analysis by Mechanism of Action
3.1.6. Analysis by Spectrum of Activity
3.1.7. Analysis by Type of Target Bacteria(s)
3.1.8. Analysis by Target Bacterial Strain(s)
3.1.9. Analysis by Target Disease Indication(s)
3.1.10. Analysis by Nature of Source
3.1.11. Analysis by Type of Therapy
3.1.12. Analysis by Route(s) of Administration
3.1.13. Analysis by Dosage Form(s)
3.1.14. Analysis by Type of Patient Population (based on Age)
3.1.15. Analysis by Type of Patient Population (based on Gender)
3.2. Approved Antibiotic Generics: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Analysis by Location of Headquarters
3.2.4. Most Active Players: Analysis by Number of Approved Generics
4. MARKET LANDSCAPE: APPROVED ANTIBIOTIC BRANDS
4.1. Approved Antibiotic Brands: Overall Market Landscape
4.1.1. Analysis by Year of Approval
4.1.2. Analysis by Region(s) of Approval
4.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
4.1.4. Analysis by Type of Antibiotic (based on Drug Class)
4.1.5. Analysis by Mechanism of Action
4.1.6. Analysis by Spectrum of Activity
4.1.7. Analysis by Type of Target Bacteria
4.1.8. Analysis by Target Bacterial Strain(s)
4.1.9. Analysis by Target Disease Indication(s)
4.1.10. Analysis by Nature of Source
4.1.11. Analysis by Type of Therapy
4.1.12. Analysis by Route(s) of Administration
4.1.13. Analysis by Dosage Form(s)
4.1.14. Analysis by Type of Patient Population (based on Age)
4.1.15. Analysis by Type of Patient Population (based on Gender)
4.1.16. Analysis by Type of Innovation
4.2. Approved Antibiotic Brands: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.4. Analysis by Location of Headquarters
4.2.5. Most Active Players: Analysis by Number of Approved Brands
5. MARKET LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS
5.1. Clinical -Stage Antibiotics: Overall Market Landscape
5.1.1. Analysis by Status of Development
5.1.2. Analysis by Stage of Development
5.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
5.1.4. Analysis by Type of Antibiotic (based on Drug Class)
5.1.5. Analysis by Mechanism of Action
5.1.6. Analysis by Spectrum of Activity
5.1.7. Analysis by Type of Target Bacteria(s)
5.1.8. Analysis by Target Bacterial Strain(s)
5.1.9. Analysis by Target Disease Indication(s)
5.1.10. Analysis by Therapeutic Area(s)
5.1.11. Analysis by Nature of Source
5.1.12. Analysis by Type of Therapy
5.1.13. Analysis by Route(s) of Administration
5.1.14. Analysis by Dosage Form(s)
5.1.15. Analysis by Dosage Strength
5.1.16. Analysis by Dosage Frequency
5.1.17. Analysis by Dosing Period
5.1.18. Analysis by Type of Patient Population (based on Age)
5.1.19. Analysis by Type of Patient Population (based on Gender)
5.1.20. Analysis by Special Designation Received
5.2. Clinical -Stage Antibiotics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Most Active Players: Analysis by Number of Clinical-stage Antibiotics
5.2.5. Most Active Players: Analysis by Number of Preclinical-stage Antibiotics
6. COMPANY PROFILES
6.1. Bristol-Myers Squibb
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Financial Information
6.1.4. Product Portfolio
6.1.5. Recent Developments
6.1.6. Key Strategies
6.1.7. Key Focus Areas
6.1.8. Expert Opinion
6.2. Daiichi Sankyo
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments
6.2.6. Key Strategies
6.2.7. Key Focus Areas
6.2.8. Expert Opinion
6.3. GlaxoSmithKline
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments
6.3.6. Key Strategies
6.3.7. Key Focus Areas
6.3.8. Expert Opinion
6.4. Melinta Therapeutics
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Financial Information
6.4.4. Product Portfolio
6.4.5. Recent Developments
6.4.6. Key Strategies
6.4.7. Key Focus Areas
6.4.8. Expert Opinion
6.5. Merck
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments
6.5.6. Key Strategies
6.5.7. Key Focus Areas
6.5.8. Expert Opinion
6.6. Pfizer
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments
6.6.6. Key Strategies
6.6.7. Key Focus Areas
6.6.8. Expert Opinion
6.7. Concluding Remarks
7. PARTNERSHIPS AND COLLABORATIONS ANALYSIS
7.1. Partnership Models
7.2. Antibiotics: List of Partnerships and Collaborations
7.2.1. Analysis by Year of Partnership
7.2.2. Analysis by Type of Partnership
7.2.3. Analysis by Type of Partner
7.2.4. Analysis by Company Size
7.2.5. Local and International Agreements
7.2.6. Intracontinental and Intercontinental Agreements
7.2.7. Most Active Players: Analysis by Number of Partnerships
7.2.8. Concluding Remarks
8. CLINICAL TRIAL ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Antibiotics: Clinical Trial Analysis
8.2.1. Analysis by Trial Registration Year
8.2.2. Analysis by Trial Status
8.2.3. Analysis by Trial Phase
8.2.4. Analysis by Type of Patient Population (based on Gender)
8.2.5 Word Cloud Analysis: Key Focus Areas
8.2.6. Analysis by Type of Sponsor
8.2.7. Analysis by Geography
8.2.8. Most Active Industry Players: Analysis by Number of Trials
8.2.9. Most Active Non-Industry Players: Analysis by Number of Trials
9. KEY OPINION LEADERS
9.1. Assumptions and Key Parameters
9.2. Methodology
9.3. Antibiotics: Key Opinion Leaders (KOLs)
9.3.1. Analysis by Type of KOL
9.3.2. Analysis by Qualification
9.3.3. Analysis by Type of Organization
9.3.4. Analysis by Affiliated Organization
9.3.5. Analysis by Geographical Location of KOLs
9.3.6. Analysis by Target Disease Indication(s)
9.3.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
9.3.8 Most Prominent KOLs: Peer Group 2 (Other Types of Investigators)
9.3.9. Most Prominent KOLs: Analysis by RA score
9.3.10. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9.3.11. Concluding Remarks
10. KEY TRENDS IN ANTIBIOTICS INDUSTRY
10.1. Antibiotics Industry: Drug-Pricing Analysis
10.2. Antibiotics Industry: Outsourcing Trends
10.3. Antibiotics Industry: Impact of COVID-19
11. APPROVED ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.3. Success Protocol Analysis of Recently Approved Antibiotic Brands
11.3.1. Dovprela (TB Alliance)
11.3.1.1. Drug Overview
11.3.1.2. Success Protocol Analysis
11.3.2. Fetroja (Shionogi)
11.3.2.1. Drug Overview
11.3.2.2. Success Protocol Analysis
11.3.4. Kimyrsa (Melinta Therapeutics)
11.3.4.1. Drug Overview
11.3.4.2. Success Protocol Analysis
11.3.5 Recarbrio (Merck)
11.3.5.1. Drug Overview
11.3.5.2. Success Protocol Analysis
11.3.6. Quofenix (Menarini)
11.3.6.1. Drug Overview
11.3.6.2. Success Protocol Analysis
11.3.9 Xenleta (Nabriva Therapeutics)
11.3.9.1. Drug Overview
11.3.9.2. Success Protocol Analysis
11.4. Concluding Remarks
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Global Antibiotics Market, 2023-2035
12.3.1. Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2035
12.3.1.1. Antibiotics Market for Aminoglycosides, 2023-2035
12.3.1.2. Antibiotics Market for Cephalosporins, 2023-2035
12.3.1.3. Antibiotics Market for Fluoroquinolones, 2023-2035
12.3.1.4. Antibiotics Market for Macrolides, 2023-2035
12.3.1.5. Antibiotics Market for Oxazolidinones, 2023-2035
12.3.1.6. Antibiotics Market for Penicillins, 2023-2035
12.3.1.7. Antibiotics Market for Sulphonamides, 2023-2035
12.3.1.8. Antibiotics Market for Tetracyclines, 2023-2035
12.3.1.9. Antibiotics Market for Other Classes, 2023-2035
12.3.2. Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035
12.3.2.1. Antibiotics Market for Bacterial Infections, 2023-2035
12.3.2.2. Antibiotics Market for Dermatological/ Skin Infections, 2023-2035
12.3.2.3. Antibiotics Market for Gastrointestinal Infections, 2023-2035
12.3.2.4. Antibiotics Market for Hematological Infections, 2023-2035
12.3.2.5. Antibiotics Market for Nephrological Infections, 2023-2035
12.3.2.6. Antibiotics Market for Pulmonary Infections, 2023-2035
12.3.2.7. Antibiotics Market for Reproductive Tract Infections, 2023-2035
12.3.2.8. Antibiotics Market for Respiratory Tract Infections, 2023-2035
12.3.2.9. Antibiotics Market for Sexually Transmitted Diseases, 2023-2035
12.3.2.10. Antibiotics Market for Urinary Tract Infections, 2023-2035
12.3.2.11. Antibiotics Market for Other Bacterial Infections, 2023-2035
12.3.3. Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035
12.3.3.1. Antibiotics Market for Monotherapies, 2023-2035
12.3.3.2. Antibiotics Market for Combination Therapies, 2023-2035
12.3.4. Antibiotics Market: Distribution by Route of Administration, 2023 and 2035
12.3.4.1. Antibiotics Market for Intravenous Therapies, 2023-2035
12.3.4.2. Antibiotics Market for Oral Therapies, 2023-2035
12.3.5. Antibiotics Market: Distribution by Geography, 2023 and 2035
12.3.5.1. Antibiotics Market in North America, 2023-2035
12.3.5.2. Antibiotics Market in Europe, 2023-2035
12.3.5.2. Antibiotics Market in Asia-Pacific, 2023-2035
12.3.5.3. Antibiotics Market in Rest of the World, 2023-2035
12.3.6. Sales Forecast: Approved Antibiotics
12.3.6.1. Aemcolo®: Sales Forecast, 2023-2035
12.3.6.2. Arikayce®: Sales Forecast, 2023-2035
12.3.6.3. Baxdela™: Sales Forecast, 2023-2035
12.3.6.4. Dalacin C: Sales Forecast, 2023-2035
12.3.6.5. Dovprela®: Sales Forecast, 2023-2035
12.3.6.6. Emrok: Sales Forecast, 2023-2035
12.3.6.7. Emrok-O: Sales Forecast, 2023-2035
12.3.6.8. Fetroja®: Sales Forecast, 2023-2035
12.3.6.9. Kimyrsa™: Sales Forecast, 2023-2035
12.3.6.10. Lasvic®: Sales Forecast, 2023-2035
12.3.6.11. Nuzyra®: Sales Forecast, 2023-2035
12.3.6.12. Orbactiv™/Tenkasi: Sales Forecast, 2023-2035
12.3.6.13. Ozanex™: Sales Forecast, 2023-2035
12.3.6.14. Quofenix: Sales Forecast, 2023-2035
12.3.6.15. Recarbrio™: Sales Forecast, 2023-2035
12.3.6.16. Seysara™: Sales Forecast, 2023-2035
12.3.6.17. Solosec®: Sales Forecast, 2023-2035
12.3.6.18. Vabomere™: Sales Forecast, 2023-2035
12.3.6.19. Xenleta™: Sales Forecast, 2023-2035
12.3.6.20. XEPI™: Sales Forecast, 2023-2035
12.3.6.21. Xerava™: Sales Forecast, 2023-2035
12.3.6.22. Xydalba®: Sales Forecast, 2023-2035
12.3.6.23. Youxitai: Sales Forecast, 2023-2035
12.3.6.24. Zemdri™: Sales Forecast, 2023-2035
12.3.6.25. Zerbaxa®: Sales Forecast, 2023-2035
12.3.6.26. Zyvoxam®: Sales Forecast, 2023-2035
12.3.7. Sales Forecast: Clinical-stage Antibiotics
12.3.7.1. Cefepime-Taniborbactam: Sales Forecast, 2023-2035
12.3.7.2. CONTEPO™: Sales Forecast, 2023-2035
12.3.7.3. Gepotidacin (GSK2140944): Sales Forecast, 2023-2035
12.3.7.4. MBK-01: Sales Forecast, 2023-2035
12.3.7.5. MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2035
12.3.7.6. Nafithromycin (WCK 4873): Sales Forecast, 2023-2035
12.3.7.7. RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, 2023-2035
12.3.7.8. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2035
12.3.7.9. Ridinilazole (SMT 19969): Sales Forecast, 2023-2035
12.3.7.10. Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2035
12.3.7.11. Tebipenem HBr: Sales Forecast, 2023-2035
12.3.7.12. WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2035
12.3.7.13. WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2035
12.3.7.14. XNW4107 (Funobactam): Sales Forecast, 2023-2035
12.3.7.15. Zabofloxacin: Sales Forecast, 2023-2035
12.3.7.16. Zoliflodacin (ETX0914): Sales Forecast, 2023-2035
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
